Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction

✍ Scribed by M.J. Forshaw; J.A. Gossage; K. Chrystal; K. Cheong; S. Atkinson; A. Botha; P.G. Harper; R.C. Mason

• Book ID: 116442654
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 121 KB
• Volume: 32
• Category: Article
• ISSN: 0748-7983
• DOI: 10.1016/j.ejso.2006.02.025

✦ Synopsis

Aims
To evaluate a single unit's experience with neoadjuvant chemotherapy for treating locally advanced non-metastatic initially resectable and unresectable oesophago-gastric cancer.

Methods
The medical records of all patients with either locally advanced carcinoma of the lower oesophagus or cardia treated with neoadjuvant chemotherapy between August 1999 and January 2003 were reviewed.

Results
Sixty-four patients with initially resectable tumours (T2-3 or N+) and 38 patients with initially unresectable tumours (T4 or M1a) received neoadjuvant chemotherapy (83% combination Epirubicin, Cisplatin and 5-Fluorouracil). Symptomatic grade III/IV toxicity was observed in 33% of patients. Chemotherapy was not completed in 20 patients because of death (5.9%) and inadequate tumour response/toxicity (13.7%). Forty-three patients (67.3%) with initially resectable tumours and 19 patients (50%) with initially unresectable tumours underwent surgery.

Conclusions
Chemotherapy in this study was associated with appreciable toxicity. Patients with initially unresectable locally advanced disease can be downstaged with neoadjuvant chemotherapy.